Cytokine-mediated activation of human ex vivo-expanded V?9V?2 T cells.
Ontology highlight
ABSTRACT: V?9V?2 T cells, the major subset of the human peripheral blood ?? T-cell, respond to microbial infection and stressed cells through the recognition of phosphoantigens. In contrast to the growing knowledge of antigen-mediated activation mechanisms, the antigen-independent and cytokine-mediated activation mechanisms of V?9V?2 T cells are poorly understood. Here, we show that interleukin (IL) -12 and IL-18 synergize to activate human ex vivo-expanded V?9V?2 T cells. V?9V?2 T cells treated with IL-12 and IL-18 enhanced effector functions, including the expression of IFN-? and granzyme B, and cytotoxicity. These enhanced effector responses following IL-12 and IL-18 treatment were associated with homotypic aggregation, enhanced expression of ICAM-1 and decreased expression of the B- and T-lymphocyte attenuator (BTLA), a co-inhibitory receptor. IL-12 and IL-18 also induced the antigen-independent proliferation of V?9V?2 T cells. Increased expression of I?B?, IL-12R?2 and IL-18R? following IL-12 and IL-18 stimulation resulted in sustained activation of STAT4 and NF-?B. The enhanced production of IFN-? and cytotoxic activity are critical for cancer immunotherapy using V?9V?2 T cells. Thus, the combined treatment of ex vivo-expanded V?9V?2 T cells with IL-12 and IL-18 may serve as a new strategy for the therapeutic activation of these cells.
SUBMITTER: Domae E
PROVIDER: S-EPMC5542238 | biostudies-literature | 2017 Jul
REPOSITORIES: biostudies-literature
ACCESS DATA